Appeal filed against EPO sofosbuvir Gilead patent decision – Life Sciences Intellectual Property Review
Appeal filed against EPO sofosbuvir Gilead patent decision Life Sciences Intellectual Property Review Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.